(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 April 2020 (09.04.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/072480 A1

(51) International Patent Classification:
C12N 15/90 (2006.01)

(21) International Application Number:
PCT/US2019/054045

(22) International Filing Date:
01 October 2019 (01.10.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/739,546 01 October 2018 (01.10.2018) US

(71) Applicants: **LONZA LTD** [CH/CH]; Lonzastrasse, 3930 Visp (CH). **BABRAHAM INSTITUTE** [GB/GB]; Babraham Hall House, Babraham, Cambridge CB22 3AT (GB). **PFIZER, INC.** [US/US]; 525 Market St., Suite 2800, San Francisco, California 94105 (US).

(72) Inventors: **O'CALLAGHAN, Peter M.**; c/o Lonza Ltd, Lonzastrasse, 3930 Visp (CH). **BEVAN, Stephen**; c/o Babraham Institute, Babraham Hall House, Babraham, Cambridge CB22 3AT (GB). **YOUNG, Robert**; c/o Lonza Ltd, Lonzastrasse, 3930 Visp (CH). **FRASER, Peter**; c/o Babraham Institute, Babraham Hall House, Babraham, Cambridge CB22 3AT (GB). **ZHANG, Lin**; c/o Pfizer, Inc., 525 Market St., Suite 2800, San Francisco, California 94105 (US).

(74) Agent: **MANGELSEN, Christina, L.** et al.; Dority & Manning, P.A., P O Box 1449, Greenville, South Carolina 29602-1449 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION

(57) Abstract: Mammalian cells are described that includes a recombination target site integrated within high integrating locus. Recombinant protein producer cell lines incorporating the mammalian cells and methods for forming the mammalian cells are also described. The high integrating loci have been developed through understanding and mapping of the three dimensional hierarchical structure of chromatin in mammalian cells. The high integrating loci are present in transcriptionally active environments that can provide both chromatin accessibility and epigenetic stability. As such, the recombinant mammalian cells can provide predictable and stable transgene production.




FIG. 1

WO 2020/072480 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*